(1 - 32 from 56
)
Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief...
www.finanznachrichten.de
Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders...
Acticor Biotech selects GPEx® Technology to develop ACT Catalent
www.catalent.com
· Acticor Biotech Selects Catalent GPEx ® Cell Line Development Technology To Develop ACT of biologic products” commented Dr. Gilles Avenard, ...
Acticor Biotech Confirms Simbec-Orion to Make Its First in Patient...
apnews.com
Dr. Gilles Avenard, CEO of Acticor Biotech commented on this decision: “This study is key for us because it initiates all the clinical development ...
Acticor Biotech raises €15.3M in Series B Financing
www.biospectrumasia.com
New financing will enable the company to launch shortly the first Phase II clinical trial of its lead candidate ACT017 inhibiting GPVI in acute ischemic...
sorted by relevance / date